A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines

American Journal of Surgery

Volumn 197, Issue 3, 2009, Pages 331-336

  Kim, Elizabeth M H ^a   Lobocki, Catherine ^a   Dubay, Linda ^a   Mittal, Vijay K ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

Breast cancer; HER 2; Trastuzumab; VEGFR

Indexed keywords

4 [(4' CHLORO 2' FLUORO)PHENYLAMINO] 6,7 DIMETHOXYQUINAZOLINE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL GROWTH; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GROWTH INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 60549087905     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.10.009     Document Type: Article

References (29)

1. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
2. Wu Y., Hooper A.T., Zhong Z., et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119 (2006) 1519-1529
3. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
4. Borg A., Tandon A.K., Sigurdsson H., et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50 (1990) 4332-4337
5. Tsutsui S., Ohno S., Murakami S., et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71 (2002) 67-75
6. McKeage K., and Perry C.M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62 (2002) 209-243
7. Ocaña A., Cruz J.J., and Pandiella A. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 29 (2006) 90-95
8. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
9. Albanell J., and Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93 (2007) 1830-1832
10. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
11. Linderholm B., Grankvist K., Wilking N., et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant therapy. J Clin Oncol 18 (2000) 1423-1431
12. Linderholm B., Tavelin B., Grankvist K., et al. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?. Br J Cancer 81 (1999) 727-732
13. Gasparini G., Toi M., Gion M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89 (1997) 139-147
14. Camp E.R., Summy J., Bauer T.W., et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005) 397-405
15. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10 (2004) 1706-1716
16. Viloria Petit A.M., Rak J., Hung M.-C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151 (1997) 1523-1530
17. Pegram M.D., and Reese D.M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 29 Suppl 11 (2002) 29-37
18. Guo P., Fang Q., Tao H.-Q., et al. Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 63 (2003) 4684-4691
19. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 237 (1999) 1-30
20. Meunier-Carpentier S., Dales J.P., Djemli A., et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 26 (2005) 977-984
21. Weigand M., Hantel P., Kreienberg R., et al. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8 (2005) 197-204
22. Nakopoulou L., Stefanaki K., Panayotopoulou E., et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 33 (2002) 863-870
23. Dales J.P., Garcia S., Bonnier P., et al. Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma. Ann Pathol 23 (2003) 297-305
24. Hennequin L.F., Thomas A.P., Johnstone C., et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 42 (1999) 5369-5389
25. Chou T., and Talalay P. Median effect/combination-index isobologram method of multiple drug effect analysis. Adv Enzym Regul 22 (1984) 27-55
26. Dirix L.Y., Vermeulen P.B., Pawinski A., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76 (1997) 238-243
27. Sledge Jr. G.W. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 29 Suppl 11 (2002) 104-110
28. Yen L., You X.-L., Al Moustafa A.-E., et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19 (2000) 3460-3469
29. Wang Y., Fei D., Vanderlaan M., et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345